Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D7LA
|
|||
| Former ID |
DAP000205
|
|||
| Drug Name |
Metformin
|
|||
| Synonyms |
657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H11N5
|
|||
| Canonical SMILES |
CN(C)C(=N)N=C(N)N
|
|||
| InChI |
1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
|
|||
| InChIKey |
XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 657-24-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9360, 608268, 4393083, 7797077, 7979913, 11112469, 11364723, 11367285, 11369847, 11372888, 11375447, 11378011, 11466032, 11467152, 11485664, 11534102, 15297229, 26038962, 29223200, 46507752, 47206702, 47216870, 47589085, 47810852, 48110542, 48110543, 48185089, 48334597, 48416229, 49698302, 49893836, 50100453, 50100454, 53788989, 56311366, 57288471, 57322135, 57665782, 76758036, 81682410, 85789453, 89779827, 92308755, 93132799, 93166855, 103508547, 104098198, 104253645, 104305401, 104669488
|
|||
| ChEBI ID |
CHEBI:6801
|
|||
| ADReCS Drug ID | BADD_D01401 ; BADD_D01402 | |||
| SuperDrug ATC ID |
A10BA02
|
|||
| SuperDrug CAS ID |
cas=000657249
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acetyl-CoA carboxylase 2 (ACACB) | Target Info | Activator | [2], [3] |
| Solute carrier family 47 member 1 (SLC47A1) | Target Info | Modulator | [4] | |
| BioCyc | Biotin-carboxyl carrier protein assembly | |||
| Fatty acid biosynthesis initiation | ||||
| KEGG Pathway | Fatty acid biosynthesis | |||
| Pyruvate metabolism | ||||
| Propanoate metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| AMPK signaling pathway | ||||
| Insulin signaling pathway | ||||
| Adipocytokine signaling pathway | ||||
| Glucagon signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | ChREBP activates metabolic gene expression | |||
| Import of palmitoyl-CoA into the mitochondrial matrix | ||||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Fatty Acid Biosynthesis | |||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| BDNF signaling pathway | ||||
| Leptin signaling pathway | ||||
| Fatty acid, triacylglycerol, and ketone body metabolism | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. | |||
| REF 3 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
| REF 4 | Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.